RESEARCH OVERVIEW – SCALP COOLING BIBLIOGRAPHY
Deengar, A, et al. “Decreased rates of chemotherapy induced alopecia in patients receiving chemotherapy (including anthracyclines) with use of scalp cooling devices.” Poster P5-10-02, San Antonio Breast Cancer Symposium, 2019.
Heery, M, et al. “Scalp Cooling: Implementing a Cold Cap Program at a Community Breast Health Center.” Clinical Journal of Oncology Nursing 2019: 23(3):237-241.
Loparco, D, et al. “Final results of scalp cooling for hair preservation: A single- institution prospective study.” Poster, European Society for Medical Oncology 2019.
Munzone, E, et al. “Preventing chemotherapy-induced alopecia: a prospective clinical trial on the efficacy and safety of a scalp-cooling system in early breast cancer patients treated with anthracyclines.” British Journal of Cancer 2019: 121, 325-331.
Paris, I, et al. “Alopecia in women undergoing chemotherapy for breast cancer and use of scalp cooling device. Impact of Scalp Cooling Device (SCD) in preventing alopecia in women undergoing chemotherapy for breast cancer.” Poster P1-11-03, San Antonio Breast Cancer Symposium, 2018.
Fischer-Cartlidge, E, et al. “Scalp Cooling: Implementation of a Program at a Multisite Organization.” Clinical Journal of Oncology Nursing 2018: 22(5), 534-541.
Rugo, H, et al. “Scalp hypothermia for preventing alopecia during chemotherapy. A systematic review and meta-analysis of randomized controlled trials.” Clinical Breast Cancer, August 2017. (online)
Katz, M, “Scalp Cooling: The prevention of chemotherapy-induced alopecia.” Clinical Journal of Oncology Nursing, August 2017.
Rugo, H, et al. “Scalp cooling with adjuvant/neoadjuvant chemotherapy for breast cancer and the risk of scalp metastases: systematic review and meta-analysis.” Breast Cancer Research and Treatment, 2017: 163:199–205.
Rugo, H, et al. “Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer.” Journal of the American Medical Association 2017: 317(6):606-614.
Ross, M, “Scalp Cooling: A literature review of efficacy, safety, and tolerability for chemotherapy-induced alopecia.” Clinical Journal of Oncology Nursing April 2016.
Drinkut, K, et al. “coolHAIR–scalp cooling to prevent chemotherapy-induced alopecia.” (Translation from German). Geburtshilfe Frauenheilkunde 2016:76-P171.*
Schaffrin-Nabe, D, et al. “Hair-mass-Index (HMI) as indicator for the efficacy of scalp cooling(SC)and the associated quality of life.” Journal of Clinical Oncology. 34. 2016. (suppl; abstr e21692)*
Cigler, T, et al. “Body Image in Women With Breast Cancer Using a Scalp Cooling System to Reduce Chemotherapy-Induced Alopecia.” Poster P5 11-17, San Antonio Breast Cancer Symposium, 2016.
Hernández R.E. et al. “Experience at the ABC Medical Center of Mexico City, 2010-2015, using the scalp cooling system DigniCap for the prevention of chemotherapy-induced alopecia.” Poster P5 11-13, San Antonio Breast Cancer Symposium, 2016.
Traub, L, et al. “Efficacy and side effects of the DigniCap system to prevent cytostatic-induced alopecia.” (Translation from German). Geburtshilfe Frauenheilkunde 2016:76-P068.*
Campenni, GM, et al. “Preventing chemotherapy-induced alopecia by scalp cooling: preliminary data from a study on the efficacy and safety of DigniCap system in breast cancer patients.” Ann Onc. Vol. 27, Supp. 4. 2016. iv63-iv64.*
Fehr, MK, et al. “Sensor-controlled scalp cooling to prevent chemotherapy-induced alopecia in Female cancer patients.” Current Oncology. Vol. 23, No. 6. December 2016. e576-e582.*
Rugo, H, et al. “Clinical Performance of the DigniCap System, a Scalp Hypothermia System, in Preventing Chemotherapy Induced Alopecia.” Abstract 9518, American Society of Clinical Oncology meeting 2015.
Schaffrin-Nabe, D, et al. “The influence of various parameters on the success of sensor- controlled scalp cooling in preventing chemotherapy-induced alopecia.” Oncology Research and Treatment. Vol. 38. 2015. 489-495.*
Udrea, A. “Scalp cooling system in preventing chemotherapy-induced alopecia: a pilot study on 108 patients – a Romanian oncology – day hospital experience.” Medisprof Oncology. Psycho-Oncology 23 (Suppl. 3): 169- 254 (2014), P1-0062.*
Friedrichs, K and M Carstensen.“Successful reduction of alopecia induced by anthracycline and taxane containing adjuvant chemotherapy in breast cancer –clinical evaluation of sensor- controlled scalp cooling.” SpringerPlus. Vol. 3, No. 500 2014. 1-7.*
Andrews, K, et al. “Crowning Glory: Is that the whole story? Implementing scalp cooling in an Australian setting.” Poster presentation at Cancer Nurses Society of Australia, 17th Winter Congress, 2014.*
Ekwall, E, et al. “Determination of the most effective cooling temperature for the prevention of chemotherapy-induced alopecia.” Molecular and Clinical Oncology. Vol. 1. 2013. 1065- 1071.*
Meunier, A, et al. “Evaluation de la tolerance et de l’efficacitéd’ un casque à refrigeration continue (DigniCap) dans la prevention de l’alopéciechimio-induite.” Presented at the Society For Science-Based Medicine, 2013.*
Kato, M, et al. “Evaluation of DigniCap System for the Prevention of Chemotherapy-induced Hair Loss in Breast Cancer Patient.” St. Gallen Oncology Conference. 2011.*
Van den Hurk CJ, Mols F, Vingerhoets AJ, Breed WP (2010) Impact of alopecia and scalp cooling on the well-being of breast cancer patients. Psych Oncol 19(7):701–709.
Byahov, M and Shevlev, O. “Alopecia prevention in chemotherapy patients. Method of controlled scalp cooling.” Meditsinskaya Cartoteka. 2006.*
Abramov, M and Semenova, I. “Cooling of the Scalp to Prevent Anticancer Chemotherapy-induced Alopecia.” Poster.*
Henriksen, T, et al. “Advanced computerized cold cap for preventing chemotherapy induced alopecia.” The European Journal of Cancer. Vol. 1, No. 5. September 2003. S369.*
Ridderheim, M, et al. “Scalp hypothermia to prevent chemotherapy-induced alopecia is effective and safe: A pilot study of a new digitized scalp-cooling system used in 74 patients. Support Care Cancer. Vol. 11. 2003. 371-377.*
Eriksson, L, et al. “Total prevention of taxoid-induced alopecia by a new model of cold cap (Dignitana).” The European Journal of Cancer. Vol. 35, Supp. 4. September 1999.*
*Clinical data has been reviewed by the FDA.
10925 Estate Lane, Suite 185
Dallas, TX 75238
226 60 Lund, Sweden
+46 46 16 30 90
PO Box 946
Baulkham Hills NSW 2153
+61 1300 309 994
+64 0800 533 272